This inventor holds 1 USPTO granted patent. Top assignee: University of California. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: The Innovative Contributions of Iordanes Karagiannides in Epigenetic Disease Treatment
Introduction
Iordanes Karagiannides, based in North Hollywood, California, is a notable inventor recognized for his contributions to the field of epigenetic disease treatment. With a focus on addressing critical health challenges, his work has the potential to significantly impact the medical community.
Latest Patents
Iordanes holds a patent for "Compositions and methods for treating epigenetic disease." This patent encompasses compounds and compositions that are capable of treating cancer or autoimmune diseases, such as Crohn's disease, along with methods of use. His innovative approach to tackling these complex diseases showcases his commitment to advancing medical science.
Career Highlights
Iordanes is affiliated with the University of California, where he leverages his expertise in research and development. His position at such a prestigious institution highlights his dedication to scientific inquiry and innovation. His work contributes to a broader understanding of epigenetic diseases and their treatments.
Collaborations
Throughout his career, Iordanes has collaborated with esteemed colleagues, including Dimitrios Iliopoulos and Michael E. Jung. These partnerships reflect a collaborative spirit in the pursuit of scientific advancements and underscore the importance of teamwork in research and innovation.
Conclusion
Iordanes Karagiannides exemplifies the innovative spirit within the medical research community. His contributions through his patent on treating epigenetic diseases demonstrate the impact that dedicated inventors can have on healthcare solutions. As he continues his work at the University of California, the possibility for further breakthroughs in the field remains promising.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
